North America taxane market is projected to register a substantial CAGR of 7.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
North America Taxane Market, By Type (Paclitaxel, Docetaxel, Cabazitaxel), Drug Type (Generics, Branded), Formulation (Liposomes, Nanoparticles, Polymeric Micelles, Others), Age Group (Adults, Geriatric), Application (Breast Cancer, Non-Small Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others) Distribution Channel (Retail Sales, Direct Tender), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
North America taxane market is categorized into seven notable segment which is type, drug type, formulation, age group, application, end user and distribution channel.
On the basis of type, the North America taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.
On the basis of application, the North America taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and other
On the basis of drug type, the North America taxane market is segmented into branded and generics
On the basis of formulation, the North America taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others
On the basis of age group, the North America taxane market is segmented into adults and geriatric
On the basis of end user, the North America taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others
On the basis of distribution channel, the North America taxane market is segmented into direct tender, retail sales
Some of the major factors contributing to the growth of the North America taxane market are:
The rise in incidence of cancer
The funding by the government and investment in research and development
Market Players:
The key market players for North America taxane market are listed below:
Panacea Biotec
RPG Life Sciences Limited.
Aureate Healthcare
Cipla Inc.
Hetero Healthcare Limited.
AqVida GmbH
Ingenus Pharmaceuticals, LLC
TABLE OF CONTENTS
1 INTRODUCTION 38
- 1.1 OBJECTIVES OF THE STUDY 38
- 1.2 MARKET DEFINITION 38
- 1.3 OVERVIEW OF NORTH AMERICA TAXANE MARKET 38
- 1.4 CURRENCY AND PRICING 40
- 1.5 LIMITATIONS 40
- 1.6 MARKETS COVERED 41
2 MARKET SEGMENTATION 45
- 2.1 MARKETS COVERED 45
- 2.2 GEOGRAPHICAL SCOPE 46
- 2.3 YEARS CONSIDERED FOR THE STUDY 47
- 2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
- 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
- 2.6 MULTIVARIATE MODELLING 52
- 2.7 MARKET APPLICATION COVERAGE GRID 52
- 2.8 TYPE LIFELINE CURVE 53
- 2.9 DBMR MARKET POSITION GRID 54
- 2.10 VENDOR SHARE ANALYSIS 56
- 2.11 SECONDARY SOURCES 57
- 2.12 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHT 62
- 4.1 PESTEL_ANALYSIS 63
- 4.2 PORTER'S FIVE FORCES MODEL 64
5 EPIDEMIOLOGY 65
6 INDUSTRIAL INSIGHTS 66
7 NORTH AMERICA TAXANE MARKET: REGULATIONS 68
8 MARKET OVERVIEW 73
- 8.1 DRIVERS 75
- 8.1.1 THE RISE IN INCIDENCE OF CANCER 75
- 8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT 76
- 8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS 76
- 8.1.4 USE OF REIMBURSEMENT FOR TAXANE 77
- 8.2 RESTRAINTS 77
- 8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS 77
- 8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT 78
- 8.2.3 RISE IN PRODUCT RECALLS 78
- 8.3 OPPORTUNITIES 79
- 8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 79
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE 79
- 8.4 CHALLENGES 80
- 8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT 80
- 8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT 80
9 NORTH AMERICA TAXANE MARKET, BY TYPE 82
- 9.1 OVERVIEW 83
- 9.2 PACLITAXEL 86
- 9.2.1 BY TYPE 86
- 9.2.1.1 SEMI-SYNTHETIC 87
- 9.2.1.2 NATURAL 87
- 9.2.2 BY STRENGTH 87
- 9.2.2.1 100MG 87
- 9.2.2.2 200MG 87
- 9.2.2.3 250MG 87
- 9.2.2.4 30MG 87
- 9.2.2.5 260MG 87
- 9.2.2.6 300MG 88
- 9.3 DOCETAXEL 88
- 9.3.1 120MG 89
- 9.3.2 80MG 89
- 9.3.3 20MG 89
- 9.3.4 40MG 89
- 9.3.5 60MG 89
- 9.4 CABAZITAXEL 89
10 NORTH AMERICA TAXANE MARKET, BY APPLICATION 91
- 10.1 OVERVIEW 92
- 10.2 BREAST CANCER 95
- 10.3 NON-SMALL CELL LUNG CANCER 95
- 10.4 PANCREATIC CANCER 96
- 10.5 OVARIAN CANCER 97
- 10.6 PROSTATE CANCER 97
- 10.7 OTHERS 98
11 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE 99
- 11.1 OVERVIEW 100
- 11.2 GENERICS 103
- 11.3 BRANDED 104
12 NORTH AMERICA TAXANE MARKET, BY FORMULATION 105
- 12.1 OVERVIEW 106
- 12.2 LIPOSOMES 109
- 12.3 NANOPARTICLES 109
- 12.4 POLYMERIC MICELLES 110
- 12.5 OTHERS 111
13 NORTH AMERICA TAXANE MARKET, BY AGE GROUP 112
- 13.1 OVERVIEW 113
- 13.2 ADULT 116
- 13.2.1 FEMALE 117
- 13.2.2 MALE 117
- 13.3 GERIATRIC 117
- 13.3.1 FEMALE 118
- 13.3.2 MALE 118
14 NORTH AMERICA TAXANE MARKET, BY END USER 119
- 14.1 OVERVIEW 120
- 14.2 HOSPITALS 123
- 14.3 AMBULATORY SURGICAL CENTERS 123
- 14.4 SPECIALTY CLINICS 124
- 14.5 OTHERS 125
15 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL 126
- 15.1 OVERVIEW 127
- 15.2 RETAIL SALES 130
- 15.2.1 HOSPITAL PHARMACY 130
- 15.2.2 RETAIL PHARMACY 131
- 15.2.3 ONLINE PHARMACY 131
- 15.3 DIRECT TENDER 131
16 NORTH AMERICA TAXANE MARKET, BY REGION 132
- 16.1 NORTH AMERICA 133
- 16.1.1 U.S. 142
- 16.1.2 CANADA 146
- 16.1.3 MEXICO 150
17 NORTH AMERICA TAXANE MARKET: COMPANY LANDSCAPE 154
- 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 154
18 SWOT ANALYSIS 155
19 COMPANY PROFILE 156
- 19.1 BRISTOL-MYERS SQUIBB COMPANY 156
- 19.1.1 COMPANY SNAPSHOT 156
- 19.1.2 REVENUE ANALYSIS 156
- 19.1.3 COMPANY SHARE ANALYSIS 157
- 19.1.4 PRODUCT PORTFOLIO 157
- 19.1.5 RECENT DEVELOPMENTS 157
- 19.2 SANOFI-AVENTIS U.S. LLC 159
- 19.2.1 COMPANY SNAPSHOT 159
- 19.2.2 REVENUE ANALYSIS 159
- 19.2.3 COMPANY SHARE ANALYSIS 160
- 19.2.4 PRODUCT PORTFOLIO 160
- 19.2.5 RECENT DEVELOPMENTS 160
- 19.3 VIATRIS INC. 162
- 19.3.1 COMPANY SNAPSHOT 162
- 19.3.2 REVENUE ANALYSIS 162
- 19.3.3 COMPANY SHARE ANALYSIS 163
- 19.3.4 PRODUCT PORTFOLIO 163
- 19.3.5 RECENT DEVELOPMENT 163
- 19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION) 164
- 19.4.1 COMPANY SNAPSHOT 164
- 19.4.2 REVENUE ANALYSIS 164
- 19.4.3 COMPANY SHARE ANALYSIS 165
- 19.4.4 PRODUCT PORTFOLIO 165
- 19.4.5 RECENT DEVELOPMENTS 166
- 19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA ) 167
- 19.5.1 COMPANY SNAPSHOT 167
- 19.5.2 REVENUE ANALYSIS 167
- 19.5.3 COMPANY SHARE ANALYSIS 168
- 19.5.4 PRODUCT PORTFOLIO 168
- 19.5.5 RECENT DEVELOPMENTS 168
- 19.6 HIKMA PHARMACEUTICALS PLC 170
- 19.6.1 COMPANY SNAPSHOT 170
- 19.6.2 REVENUE ANALYSIS 170
- 19.6.3 PRODUCT PORTFOLIO 171
- 19.6.4 RECENT DEVELOPMENTS 171
- 19.7 ACCORD HEALTHCARE 172
- 19.7.1 COMPANY SNAPSHOT 172
- 19.7.2 PRODUCT PORTFOLIO 172
- 19.7.3 RECENT DEVELOPMENTS 172
- 19.8 AQVIDA GMBH 173
- 19.8.1 COMPANY SNAPSHOT 173
- 19.8.2 PRODUCT PORTFOLIO 173
- 19.8.3 RECENT DEVELOPMENTS 173
- 19.9 AUREATE HEALTHCARE 174
- 19.9.1 COMPANY SNAPSHOT 174
- 19.9.2 PRODUCT PORTFOLIO 174
- 19.9.3 RECENT DEVELOPMENTS 174
- 19.10 CIPLA INC. 175
- 19.10.1 COMPANY SNAPSHOT 175
- 19.10.2 REVENUE ANALYSIS 175
- 19.10.3 PRODUCT PORTFOLIO 176
- 19.10.4 RECENT DEVELOPMENTS 176
- 19.11 DR. REDDY'S LABORATORIES LTD. 177
- 19.11.1 COMPANY SNAPSHOT 177
- 19.11.2 REVENUE ANALYSIS 177
- 19.11.3 PRODUCT PORTFOLIO 178
- 19.11.4 RECENT DEVELOPMENTS 178
- 19.12 ELEVAR THERAPEUTICS 179
- 19.12.1 COMPANY SNAPSHOT 179
- 19.12.2 PRODUCT PORTFOLIO 179
- 19.12.3 RECENT DEVELOPMENTS 179
- 19.13 HETERO HEALTHCARE LIMITED. 181
- 19.13.1 COMPANY SNAPSHOT 181
- 19.13.2 PRODUCT PORTFOLIO 181
- 19.13.3 RECENT DEVELOPMENTS 181
- 19.14 HUIANG PHARMACEUTICAL CO LTD 182
- 19.14.1 COMPANY SNAPSHOT 182
- 19.14.2 PRODUCT PORTFOLIO 182
- 19.14.3 RECENT DEVELOPMENTS 182
- 19.15 INGENUS PHARMACEUTICALS, LLC 183
- 19.15.1 COMPANY SNAPSHOT 183
- 19.15.2 PRODUCT PORTFOLIO 183
- 19.15.3 RECENT DEVELOPMENTS 183
- 19.16 LUYE PHARMA GROUP 184
- 19.16.1 COMPANY SNAPSHOT 184
- 19.16.2 REVENUE ANALYSIS 184
- 19.16.3 PRODUCT PORTFOLIO 185
- 19.16.4 RECENT DEVELOPMENTS 185
- 19.17 PANACEA BIOTEC 186
- 19.17.1 COMPANY SNAPSHOT 186
- 19.17.2 REVENUE ANALYSIS 186
- 19.17.3 PRODUCT PORTFOLIO 187
- 19.17.4 RECENT DEVELOPMENTS 187
- 19.18 PFIZER INC. 188
- 19.18.1 COMPANY SNAPSHOT 188
- 19.18.2 REVENUE ANALYSIS 188
- 19.18.3 PRODUCT PORTFOLIO 189
- 19.18.4 RECENT DEVELOPMENTS 189
- 19.19 RPG LIFE SCIENCES LIMITED 190
- 19.19.1 COMPANY SNAPSHOT 190
- 19.19.2 REVENUE ANALYSIS 190
- 19.19.3 PRODUCT PORTFOLIO 191
- 19.19.4 RECENT DEVELOPMENTS 191
- 19.20 SAMARTH LIFE SCIENCES PVT. LTD. 192
- 19.20.1 COMPANY SNAPSHOT 192
- 19.20.2 PRODUCT PORTFOLIO 192
- 19.20.3 RECENT DEVELOPMENTS 192
- 19.21 SAMYANG HOLDINGS CORPORATION. 193
- 19.21.1 COMPANY SNAPSHOT 193
- 19.21.2 REVENUE ANALYSIS 193
- 19.21.3 PRODUCT PORTFOLIO 194
- 19.21.4 RECENT DEVELOPMENTS 194
- 19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC. 195
- 19.22.1 COMPANY SNAPSHOT 195
- 19.22.2 PRODUCT PORTFOLIO 195
- 19.22.3 RECENT DEVELOPMENTS 195
- 19.23 TORRENT PHARMACEUTICALS LTD 196
- 19.23.1 COMPANY SNAPSHOT 196
- 19.23.2 REVENUE ANALYSIS 196
- 19.23.3 PRODUCT PORTFOLIO 197
- 19.23.4 RECENT DEVELOPMENTS 197
- 19.24 TAXANE HEALTHCARE 198
- 19.24.1 COMPANY SNAPSHOT 198
- 19.24.2 PRODUCT PORTFOLIO 198
- 19.24.3 RECENT DEVELOPMENTS 198
20 QUESTIONNAIRE 199
21 RELATED REPORTS 202